唑尼沙胺辅助左旋多巴治疗DLB帕金森症状的2期随机双盲试验
这项2期随机双盲安慰剂对照研究纳入158例很可能DLB门诊患者,评估唑尼沙胺25或50 mg每日一次辅助左旋多巴治疗12周的疗效与安全性。第12周唑尼沙胺50 mg组UPDRS第3部分总分较基线的改善显著优于安慰剂组(组间差-4.1,95%CI -6.8至-1.4,p=0.003),且未加重认知功能、BPSD或照护者负担。
要点
- 唑尼沙胺50 mg辅助左旋多巴可显著改善DLB患者运动症状。
- 唑尼沙胺未加重认知功能、精神行为症状或照护者负担。
- 50 mg组不良事件总体发生率高于25 mg组和安慰剂组。
核心结论
- 唑尼沙胺辅助左旋多巴可改善DLB伴随的帕金森症状,且不加重认知功能或精神症状。
- 该研究提供I级证据支持唑尼沙胺辅助左旋多巴改善DLB患者帕金森症状且耐受性良好。
研究设计与样本
- 2期安慰剂对照随机双盲研究,含4周安慰剂导入期和12周治疗期。
- 治疗期为安慰剂或唑尼沙胺25 mg或50 mg每日一次;158例很可能DLB门诊患者接受研究药物,21例治疗期间中止、137例完成治疗。
主要发现
- 第12周UPDRS第3部分总分改善在唑尼沙胺50 mg组显著大于安慰剂组(组间差-4.1;95%CI -6.8至-1.4;p=0.003)。
- 唑尼沙胺未加重认知功能、BPSD或照护者负担。
- 不良事件总体发生率:唑尼沙胺50 mg组65.3%、25 mg组43.1%、安慰剂组50.0%;各组严重不良事件发生率相似。
关键数值与推荐
- 主要终点为第12周UPDRS第3部分总分较基线的变化。
- 唑尼沙胺50 mg组与安慰剂组UPDRS第3部分总分变化的组间差为-4.1(95%CI -6.8至-1.4;p=0.003)。
- 不良事件总体发生率在唑尼沙胺50 mg组为65.3%、25 mg组为43.1%、安慰剂组为50.0%。
临床怎么用
- 对DLB伴帕金森症状患者,可考虑在左旋多巴基础上加用唑尼沙胺50 mg每日一次以改善运动症状。
- 用药期间需关注不良事件,50 mg组总体不良事件发生率高于25 mg组和安慰剂组。
- 唑尼沙胺未加重认知功能与BPSD,但仍需个体化评估后使用。
局限性
- 为2期研究,治疗期仅12周,长期疗效与安全性未涵盖。
- 摘要未报告认知功能、BPSD及照护者负担的具体数值结果。
- 摘要未报告各组具体严重不良事件类型与发生率数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy and safety of zonisamide as an adjunct to levodopa therapy for parkinsonism in patients with dementia with Lewy bodies (DLB). METHODS: This phase 2, placebo-controlled, randomized, double-blind study consisted of run-in (placebo, 4 weeks) and treatment (placebo or zonisamide 25 or 50 mg once daily, 12 weeks) periods. Outpatients diagnosed with probable DLB were eligible for inclusion. The primary endpoint was the change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS) part 3 total score at week 12. Cognitive function, behavioral and psychological symptoms of dementia (BPSD), caregiver burden, other UPDRS parts as secondary endpoints, and safety were also assessed. RESULTS: Overall, 158 patients with DLB received the study drug; 21 discontinued during treatment and 137 completed treatment. Improvement in UPDRS part 3 total score at week 12 was significantly greater in the zonisamide 50 mg group compared with placebo (between-group difference -4.1; 95% confidence interval -6.8 to -1.4; p = 0.003). Zonisamide did not worsen cognitive function, BPSD, or caregiver burden. The overall incidence of adverse events was higher in the zonisamide 50 mg than the 25 mg and placebo groups (65.3%, 43.1%, and 50.0%, respectively); similar rates of serious adverse events were observed among all groups. CONCLUSION: Zonisamide (adjunctive to levodopa) improved parkinsonism accompanying DLB without worsening cognitive function or psychiatric symptoms. CLINICAL TRIAL REGISTRATION: JapicCTI-122040. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that zonisamide (adjunctive to levodopa) improves parkinsonism and is well-tolerated in patients with DLB.
引用
- Murata M, Odawara T, Hasegawa K, et al. Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study. Neurology. 2018. PMID: 29367449. doi:10.1212/WNL.0000000000005010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。